{"DataElement":{"publicId":"5026557","version":"1","preferredName":"Agent Intervention Disease or Disorder Status Code Indicator","preferredDefinition":"A coded response for questions related to the use of agents that produce an effect, or that are intended to alter the course of a disease in a patient, and the status of the patient's disease.","longName":"AGNT_INT_DZ_STS_IND","context":"Theradex","contextVersion":"1","DataElementConcept":{"publicId":"5026533","version":"1","preferredName":"Agent Intervention or Procedure Disease or Disorder Status","preferredDefinition":"An active power or cause (as principle, substance, physical or biological factor, etc.) that produces a specific effect._An activity that produces an effect, or that is intended to alter the course of a disease in a patient or population. This is a general term that encompasses the medical, social, behavioral, and environmental acts that can have preventive, therapeutic, or palliative effects._Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. The term is often used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function._A condition or state at a particular time.","longName":"2223333v1.0:5026531v1.0","context":"Theradex","contextVersion":"1","ObjectClass":{"publicId":"2223333","version":"1","preferredName":"Agent","preferredDefinition":"An active power or cause (as principle, substance, physical or biological factor, etc.) that produces a specific effect. (NCI)","longName":"C1708","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Agent","conceptCode":"C1708","definition":"An active power or cause (as principle, substance, physical or biological factor, etc.) that produces a specific effect.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F62B10F2-76A7-2830-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-05-02","endDate":null,"createdBy":"UMLLOADER","dateCreated":"2005-05-02","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"5026531","version":"1","preferredName":"Intervention or Procedure Disease or Disorder Status","preferredDefinition":"An activity that produces an effect, or that is intended to alter the course of a disease in a patient or population. This is a general term that encompasses the medical, social, behavioral, and environmental acts that can have preventive, therapeutic, or palliative effects.:Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. The term is often used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function.:A condition or state at a particular time.","longName":"C25218:C2991:C25688","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Intervention or Procedure","conceptCode":"C25218","definition":"An activity that produces an effect, or that is intended to alter the course of a disease in a patient or population. This is a general term that encompasses the medical, social, behavioral, and environmental acts that can have preventive, therapeutic, or palliative effects.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Disease or Disorder","conceptCode":"C2991","definition":"Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. The term is often used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Status","conceptCode":"C25688","definition":"A condition or state at a particular time.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"20E2CCF0-ED32-0D47-E050-BB89AD434682","latestVersionIndicator":"Yes","beginDate":"2015-09-29","endDate":null,"createdBy":"TAYLORT","dateCreated":"2015-09-29","modifiedBy":"ONEDATA","dateModified":"2015-09-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008556","version":"1","preferredName":"Assessment Results","preferredDefinition":"the results of evaluations of the patient and the patient's disease.","longName":"ASSESS_RESULTS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B2D08DE9-38BB-7208-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-27","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-27","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"20E2CCF0-ED43-0D47-E050-BB89AD434682","latestVersionIndicator":"Yes","beginDate":"2015-09-29","endDate":null,"createdBy":"TAYLORT","dateCreated":"2015-09-29","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":"9/30/15 released/tt_9/29/15 tt.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"3298541","version":"1","preferredName":"Yes No Not Applicable Code Indicator","preferredDefinition":"Indicator to represent a response of Yes, No, or Not Applicable._The affirmative response to a question or activity._The non-affirmative response to a question._Determination that a value is not relevant in the current context._A system of numbered categories for representation of data.","longName":"YES_NO_NA_CD_IND","context":"CCR","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":"1","maxLength":"1","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"X","valueDescription":"Not applicable","ValueMeaning":{"publicId":"2581003","version":"1","preferredName":"Not applicable","longName":"2581003v1.00","preferredDefinition":"Determination of a value is not relevant in the current context.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Not Applicable","conceptCode":"C48660","definition":"Determination of a value is not relevant in the current context.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0978-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-12-31","endDate":null,"createdBy":"SBREXT","dateCreated":"2003-12-31","modifiedBy":"CLOHNES","dateModified":"2023-11-09","changeDescription":null,"administrativeNotes":"2023.3.6 Added Alt VM-COG. ak","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B04AC04D-C223-0627-E040-BB89AD432C31","beginDate":"2002-02-11","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-27","modifiedBy":"ONEDATA","dateModified":"2011-10-27","deletedIndicator":"No"},{"value":"N","valueDescription":"No","ValueMeaning":{"publicId":"2559515","version":"1","preferredName":"No","longName":"2559515","preferredDefinition":"The non-affirmative response to a question.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"No","conceptCode":"C49487","definition":"The non-affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B588-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"GDEEN","dateModified":"2024-01-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B04AC04D-C22D-0627-E040-BB89AD432C31","beginDate":"2002-08-22","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-27","modifiedBy":"ONEDATA","dateModified":"2011-10-27","deletedIndicator":"No"},{"value":"Y","valueDescription":"Yes","ValueMeaning":{"publicId":"2560453","version":"1","preferredName":"Yes","longName":"2560453","preferredDefinition":"The affirmative response to a question or activity.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Yes","conceptCode":"C49488","definition":"The affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B932-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"CLOHNES","dateModified":"2023-09-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B04AC04D-C237-0627-E040-BB89AD432C31","beginDate":"2002-08-22","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-27","modifiedBy":"ONEDATA","dateModified":"2011-10-27","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008551","version":"1","preferredName":"Assessments","preferredDefinition":"evaluations of the patient and the patient's disease.","longName":"ASSESS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22DA727-6718-5A2D-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"3298540","version":"1","preferredName":"Yes No Not Applicable Code Indicator","preferredDefinition":"The affirmative response to a question or activity.:The non-affirmative response to a question.:Determination that a value is not relevant in the current context.:A system of numbered categories for representation of data.:An event, entity or condition that typically characterizes a prescribed environment or situation and determines or aids in determining whether certain stated circumstances exist or criteria are satisfied.","longName":"3298540v1.0","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Yes","conceptCode":"C49488","definition":"The affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"No","conceptCode":"C49487","definition":"The non-affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Not Applicable","conceptCode":"C48660","definition":"Determination of a value is not relevant in the current context.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Code","conceptCode":"C25162","definition":"A symbol or combination of symbols which is assigned to the members of a collection.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Indicator","conceptCode":"C25180","definition":"An event, entity or condition that typically characterizes a prescribed environment or situation and determines or aids in determining whether certain stated circumstances exist or criteria are satisfied.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B04AC04D-C1F2-0627-E040-BB89AD432C31","latestVersionIndicator":"Yes","beginDate":"2011-10-27","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-27","modifiedBy":"ONEDATA","dateModified":"2011-10-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"CTMS:Clinical Trials Monitoring Service","workflowStatus":"RELEASED","registrationStatus":"Application","id":"B04AC04D-C203-0627-E040-BB89AD432C31","latestVersionIndicator":"Yes","beginDate":"2011-10-27","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-27","modifiedBy":"MAESKEB","dateModified":"2016-01-20","changeDescription":"Created to support Theradex design of CRFs for NCI CCR trials","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"3876352","version":"1","longName":"Inclusion Criteria","context":"Theradex","ClassificationSchemeItems":[{"publicId":"3876422","version":"1","longName":"Disease Status & Genetics","context":"Theradex"},{"publicId":"10000494","version":"1","longName":"Prior Treatments","context":"Theradex"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"If patient is in the dose exp","type":"Preferred Question Text","description":"If patient is in the dose expansion portion ONLY, does patient have: 1) progression of disease with first line osimertinib administered for advanced or metastatic disease as the last previous systemic treatment 2) be treatment naïve for other 3rd generation EGFR-TKI (CO-1686) and mTOR inhibitors?","url":null,"context":"Theradex"},{"name":"Theradex - 2","type":"Alternate Question Text","description":"If patient is on the dose expansion portion, does patient have: 1) have a tumor which is EGFR-T790M positive using central genotyping (if EGFR-T790M status is unknown, patients may consent for central EGFR T790M testing as part of screening for the trial; patients who test negative for EGFR T790M by central genotyping will be ineligible), and 2) be treatment naïve to T790M-directed EGFR TKI (e.g. AZD9291, rociletinib, etc.)?","url":null,"context":"Theradex"},{"name":"Theradex - 1","type":"Alternate Question Text","description":"For the dose expansion portion ONLY, does patient have: 1) have progression of disease with erlotinib, gefitinib or afatinib as last previous systemic treatment, 2) tumors must be EGFR-T790M negative confirmed by central testing prior to treatment (If EGFR-T790M status is unknown patients may consent for trial for biopsy and testing for EGFR T790M will be performed as part of initial biopsy for trial; patients who test positive for EGFR T790M by central testing will be ineligible for the dose expansion), 3) be treatment naïve to 3rd generation EGFR-TKI (CO-1686 and AZD9291) and EGFR monoclonal antibodies?","url":null,"context":"Theradex"},{"name":"Theradex - 3","type":"Alternate Question Text","description":"If patient is in the dose expansion portion ONLY, does patient have: 1) progression of disease with erlotinib, gefitinib or afatinib as last previous systemic treatment, 2) tumors must be EGFR T790M negative confirmed by central testing prior to treatment (If EGFR-T790M status is unknown, patient may consent for trial for biopsy and testing for EGFR T790M will be performed as part of the initial biopsy for the trial: patients who test positive for EGFR T790M by central testing will be ineligible for the dose expansion), 3) be treatment naïve for 3rd generation EGFR-TKI (CO-1686 and osimertinib (AZD9291)) and mTOR inhibitors?","url":null,"context":"Theradex"},{"name":"Theradex - 4","type":"Alternate Question Text","description":"Has prior ACT therapy been completed, and residual disease has been documented by either radiographic progression or active disease observed on biopsy (i.e. hematologic or solid tumor malignancy must be deemed active by the treating investigator)?","url":null,"context":"Theradex"},{"name":"Theradex - 5","type":"Alternate Question Text","description":"If patient has NSCLC (Cohort 1) was there evidence of radiologic or clinical disease progression during previous treatment with systemic PD-1 directed therapy and/or patient was deemed not to have derived clinical benefit from PD-1 directed treatment?","url":null,"context":"Theradex"},{"name":"Theradex - 6","type":"Alternate Question Text","description":"For patient registered to  Dose Expansion Cohort A, does patient have: 1) progression of disease on erlotinib, gefitinib or afatinib as last previous systemic treatment, 2) biopsy of tumor taken after progression on erlotinib, gefitinib or afatinib must be EGFR-T790M negative confirmed by central testing prior to treatment If EGFR-T790M status is unknown patients may consent for trial and for biopsy, and testing for EGFR T790M will be performed as part of initial biopsy for trial., 3) be treatment naïve to 3rd generation EGFR-TKI (rociletinib, HM61713 and AZD9291) and EGFR monoclonal antibodies?","url":null,"context":"Theradex"},{"name":"Theradex - 7","type":"Alternate Question Text","description":"For Dose Expansion Cohort D: patient must have: 1) tumor that harbors an  EGFR Exon 20 insertion by a CLIA certified test, and 2) have progressive disease on or aftter platinum based chemotherapy, and 3) be treatment naïve to both EGFR-TKI and EGFR monoclonal antibody?  Does For patient registered to  Dose Expansion Cohort A, does patient have: 1) progression of disease on erlotinib, gefitinib or afatinib as last previous systemic treatment, 2) biopsy of tumor taken after progression on erlotinib, gefitinib or afatinib must be EGFR-T790M negative confirmed by central testing prior to treatment (if EGFR-T790M status is unknown patients may consent for trial and for biopsy, and testing for EGFR T790M will be performed as part of initial biopsy for trial), and 3) be treatment naïve to 3rd generation EGFR-TKI (rociletinib, HM61713 and AZD9291) and EGFR monoclonal antibodies?","url":null,"context":"Theradex"},{"name":"Theradex - 8","type":"Alternate Question Text","description":"For patient registered to  Dose Expansion Cohort A, does patient have: 1) progression of disease on erlotinib, gefitinib or afatinib as last previous systemic treatment, 2) biopsy of tumor taken after progression on erlotinib, gefitinib or afatinib must be EGFR-T790M negative confirmed by central testing prior to treatment (if EGFR-T790M status is unknown patients may consent for trial and for biopsy, and testing for EGFR T790M will be performed as part of initial biopsy for trial), and 3) be treatment naïve to 3rd generation EGFR-TKI (rociletinib, HM61713 and AZD9291) and EGFR monoclonal antibodies?","url":null,"context":"Theradex"},{"name":"Theradex - 9","type":"Alternate Question Text","description":"Has patient received anti-PD-1 or anti-PD-L1 therapy with a best response of progressive disease or stable disease lasting less than or equal to 4 months (primary resistance to anti-PD-1 or anti-PD-L1 therapy?","url":null,"context":"Theradex"},{"name":"Theradex - 10","type":"Alternate Question Text","description":"If patient is on the dose expansion portion, does patient have: 1) have a tumor which is EGFR-T790M positive and 2) be treatment naïve to T790M-directed EGFR TKI (e.g. AZD9291, rociletinib, etc)?","url":null,"context":"Theradex"},{"name":"Theradex - 13","type":"Alternate Question Text","description":"If patient is registered to the dose escalation cohort, prior receipt of docetaxel is permitted and measurable disease will not be required for enrollment?","url":null,"context":"Theradex"},{"name":"Theradex -  12","type":"Alternate Question Text","description":"If patient is registered to the dose expansion cohort, prior receipt of docetaxel is permitted and measurable disease will not be required for enrollment?","url":null,"context":"Theradex"},{"name":"Theradex - 15","type":"Alternate Question Text","description":"Has patient received prior treatment with a Pi3 kinase inhibitor, anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CTLA-4 antibody, or any other antibody or drug specifically targeting T-cell co-stimulation or immune checkpoint pathways?","url":null,"context":"Theradex"},{"name":"Theradex - 16","type":"Alternate Question Text","description":"If patient has NSCLC/SCCHN/bladder Cancer/cSCC (Cohort 1) was there evidence of radiologic or clinical disease progression during previous treatment with systemic PD-1 directed therapy and/or patient was deemed not to have derived clinical benefit from PD-1 directed treatment?","url":null,"context":"Theradex"},{"name":"Theradex - 17","type":"Alternate Question Text","description":"Dose Expansion cohort: Does patient have Stage IV or recurrent/metastatic NSCLC harboring NFE2L2 or KEAP1 mutation (LSCC)?","url":null,"context":"Theradex"},{"name":"Theradex - 11","type":"Alternate Question Text","description":"Has patient received anti-PD-1 or anti-PD-L1 therapy given as monotherapy or in combination with other agents?","url":null,"context":"Theradex"},{"name":"Theradex - 14","type":"Alternate Question Text","description":"Dose Escalation Cohorts: Does patient have a solid tumor which irinotecan or topotecan is considered the standard of care?","url":null,"context":"Theradex"},{"name":"Theradex - 18","type":"Alternate Question Text","description":"Dose Expansion cohort: Does patient have Stage IV or recurrent/metastatic NSCLC harboring 1) NFE2L2 mutations (LSCC); 2) KEAP1 mutations (LSCC); KRAS/KEAP1 or KRAS/NFE2L2 co-mutations (non-squamous NSCLC); or 3) LSCC WT for NFE2L2 or KEAP1 who have progressed on or after platinum-based chemotherapy and/or PD-(L)1 immune checkpoint inhibitors or immunotherapy?","url":null,"context":"Theradex"}],"origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"20E2CCF0-EE29-0D47-E050-BB89AD434682","latestVersionIndicator":"Yes","beginDate":"2015-09-29","endDate":null,"createdBy":"TAYLORT","dateCreated":"2015-09-29","modifiedBy":"SOKKERL","dateModified":"2024-01-25","changeDescription":"12/5/16 tt, added CSI. 9/30/15 approved & released/tt_9/29/15 curated for 9910/tt.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}